Published in J Clin Invest on May 01, 1998
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood (2005) 3.65
Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol (2012) 3.50
Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. Blood (2014) 1.78
In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood (2008) 1.67
NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood (2010) 1.49
Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. Proc Natl Acad Sci U S A (2006) 1.47
Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. Blood (2006) 1.27
Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD). Philos Trans R Soc Lond B Biol Sci (2005) 1.26
Acute graft-versus-host disease: a bench-to-bedside update. Blood (2014) 1.23
The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol Rev (2014) 1.16
Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Front Immunol (2013) 1.10
NK cells--from bench to clinic. Biol Blood Marrow Transplant (2012) 1.08
HDAC inhibition and graft versus host disease. Mol Med (2011) 1.02
Tissue-specific homing and expansion of donor NK cells in allogeneic bone marrow transplantation. J Immunol (2009) 1.01
Biology of chronic graft-versus-host disease: implications for a future therapeutic approach. Keio J Med (2008) 0.99
Dichotomous role of interferon-gamma in allogeneic bone marrow transplant. Biol Blood Marrow Transplant (2009) 0.97
Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. Haematologica (2014) 0.94
Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice. J Clin Immunol (2002) 0.94
The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity. Immunol Rev (2014) 0.91
Use of natural killer cells as immunotherapy for leukaemia. Best Pract Res Clin Haematol (2008) 0.91
NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype. J Immunol (2015) 0.91
Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease. Expert Opin Pharmacother (2008) 0.87
Identification and characterization of the specific murine NK cell subset supporting graft-versus-leukemia- and reducing graft-versus-host-effects. Oncoimmunology (2015) 0.86
Pleiotropic effects of transforming growth factor-β in hematopoietic stem-cell transplantation. Transplantation (2010) 0.86
Human Umbilical Cord-Derived Mesenchymal Stem Cells Utilize Activin-A to Suppress Interferon-γ Production by Natural Killer Cells. Front Immunol (2014) 0.85
Plasmacytoid precursor dendritic cells from NOD mice exhibit impaired function: are they a component of diabetes pathogenesis? Diabetes (2008) 0.85
NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell Engraftment. Stem Cells Int (2016) 0.83
Functional Reconstitution of Natural Killer Cells in Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol (2016) 0.83
Rapid generation of a functional NK-cell compartment. Blood (2007) 0.83
IL-12/15/18-preactivated NK cells suppress GvHD in a mouse model of mismatched hematopoietic cell transplantation. Eur J Immunol (2015) 0.82
TLR4 inactivation protects from graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Cell Mol Immunol (2012) 0.82
Adoptive Transfer of Treg Cells Combined with Mesenchymal Stem Cells Facilitates Repopulation of Endogenous Treg Cells in a Murine Acute GVHD Model. PLoS One (2015) 0.81
Relation between Acute GVHD and NK Cell Subset Reconstitution Following Allogeneic Stem Cell Transplantation. Front Immunol (2016) 0.80
Lymphoid reconstruction and vaccines. Biol Blood Marrow Transplant (2007) 0.78
"No donor"? Consider a haploidentical transplant. Blood Rev (2014) 0.78
Advances in haploidentical stem cell transplantation. Rev Bras Hematol Hemoter (2011) 0.77
Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects. Immunotherapy (2010) 0.77
Nonmyeloablative stem cell transplantation as immunotherapy for kidney cancer and other metastatic solid tumors. Cytotechnology (2003) 0.76
Immunological aspects of Candida and Aspergillus systemic fungal infections. Interdiscip Perspect Infect Dis (2013) 0.76
Blockade of Vascular Endothelial Growth Factor (VEGF) Aggravates the Severity of Acute Graft-versus-host Disease (GVHD) after Experimental Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). Immune Netw (2011) 0.76
Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation. Front Immunol (2017) 0.76
Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation. Front Immunol (2017) 0.75
Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection. Front Immunol (2017) 0.75
Strategies in haploidentical stem cell transplantation in adults. Turk J Haematol (2013) 0.75
Targeting deacetylases to improve outcomes after allogeneic bone marrow transplantation. Trans Am Clin Climatol Assoc (2013) 0.75
Engineering haploidentical transplants. Bone Marrow Transplant (2015) 0.75
Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors-A Retrospective Study. PLoS One (2017) 0.75
Administration of α-Galactosylceramide Improves Adenine-Induced Renal Injury. Mol Med (2015) 0.75
A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma. Front Immunol (2017) 0.75
Biology of natural killer cells. Adv Immunol (1989) 14.77
Graft-versus-host disease. N Engl J Med (1991) 5.35
In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol (1981) 3.34
Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol (1989) 3.00
Bone marrow transplantation. N Engl J Med (1994) 2.83
T-cell depletion of HLA-identical transplants in leukemia. Blood (1991) 2.25
Antibodies to IFN-gamma prevent immunologically mediated intestinal damage in murine graft-versus-host reaction. Immunology (1989) 1.91
Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med (1988) 1.73
Interleukin-12 inhibits murine graft-versus-host disease. Blood (1995) 1.30
Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc Natl Acad Sci U S A (1990) 1.12
Increasing utilization of allogeneic bone marrow transplantation. Results of the 1988-1990 survey. Ann Intern Med (1992) 1.04
Transforming growth factor-beta and the immune system. Prog Growth Factor Res (1991) 1.00
Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor. J Clin Invest (1991) 0.98
Interleukin-2-activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo. Blood (1992) 0.96
TGF-beta mediates natural suppressor activity of IL-2-activated lymphocytes. J Immunol (1994) 0.94
Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation. J Immunol (1992) 0.92
Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in mice. Transplantation (1995) 0.89
Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation. Bone Marrow Transplant (1989) 0.88
Natural killer cells and bone marrow transplantation. J Natl Cancer Inst (1993) 0.88
Prevention of murine graft-versus-host disease by inducing and eliminating ASGM1+ cells of donor origin. Transplantation (1988) 0.88
Bone marrow transplantation. Transplant Proc (1995) 0.87
IL-2-induced GVHD protection is not inhibited by cyclosporine and is maximal when IL-2 is given over a 25 h period beginning on the day following bone marrow transplantation. Bone Marrow Transplant (1995) 0.86
Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells. Br J Haematol (1996) 0.85
The mechanism of IL-2-mediated protection against GVHD in mice. II. Protection occurs independently of NK/LAK cells. Transplantation (1992) 0.82
Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A (1980) 30.08
Selective in vitro growth of T lymphocytes from normal human bone marrows. Science (1976) 15.73
Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci U S A (1978) 9.59
Structure of the 5' ends of immunoglobulin genes: a novel conserved sequence. Proc Natl Acad Sci U S A (1984) 7.74
NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med (1984) 6.45
Functional and morphologic characterization of human T cells continuously grown in vitro. J Immunol (1977) 6.30
Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (1992) 5.94
Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J Immunol (1991) 5.02
Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon gamma and lipopolysaccharide. Proc Natl Acad Sci U S A (1993) 4.73
Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med (1984) 4.73
Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line. Virology (1981) 4.68
Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sézary T-cell leukaemia. Nature (1981) 4.38
Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood (2000) 4.34
Identification of a novel Y branch structure as an intermediate in trypanosome mRNA processing: evidence for trans splicing. Cell (1986) 4.31
Spontaneous release of a factor with properties of T cell growth factor from a continuous line of primate tumor T cells. J Immunol (1981) 4.27
Characterization and distribution of nucleic acid sequences of a novel type C retrovirus isolated from neoplastic human T lymphocytes. Proc Natl Acad Sci U S A (1981) 4.24
Long-term culture of human antigen-specific cytotoxic T-cell lines. J Exp Med (1978) 3.80
The promise of comparative genomics in mammals. Science (1999) 3.67
The fine specificity of antigen and Ia determinant recognition by T cell hybridoma clones specific for pigeon cytochrome c. Cell (1982) 3.38
Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J Exp Med (1981) 3.30
Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med (1999) 3.18
T-cell growth factor-mediated T-cell proliferation. Ann N Y Acad Sci (1979) 3.16
Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med (1995) 2.99
Expression of the nitric oxide synthase gene in mouse macrophages activated for tumor cell killing. Molecular basis for the synergy between interferon-gamma and lipopolysaccharide. J Biol Chem (1993) 2.96
T-cell lines established from human T-lymphocytic neoplasias by direct response to T-cell growth factor. Proc Natl Acad Sci U S A (1980) 2.89
Involvement of valosin-containing protein, an ATPase Co-purified with IkappaBalpha and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IkappaBalpha. J Biol Chem (1998) 2.80
Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethylsulfoxide. J Exp Med (1979) 2.80
Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem (1996) 2.78
Immunological properties of a type C retrovirus isolated from cultured human T-lymphoma cells and comparison to other mammalian retroviruses. J Virol (1981) 2.72
Chemokines and T lymphocyte activation: I. Beta chemokines costimulate human T lymphocyte activation in vitro. J Immunol (1996) 2.62
Death in the AIDS patient: role of cytomegalovirus. N Engl J Med (1983) 2.61
Human T-lymphocyte growth factor: regulation of growth and function of T lymphocytes. Blood (1981) 2.58
Detection of the human T cell lymphoma virus p19 in cells of some patients with cutaneous T cell lymphoma and leukemia using a monoclonal antibody. J Exp Med (1981) 2.47
Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol (1999) 2.38
Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest (1995) 2.29
Absence of the Lyt-2-,L3T4+ lineage of T cells in mice treated neonatally with anti-I-A correlates with absence of intrathymic I-A-bearing antigen-presenting cell function. J Exp Med (1985) 2.27
Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. Am J Med (1985) 2.18
Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med (1994) 2.18
An interferon-gamma-activated site (GAS) is necessary for full expression of the mouse iNOS gene in response to interferon-gamma and lipopolysaccharide. J Biol Chem (1997) 2.17
Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun (1997) 2.14
Interleukin 2 receptors on human B cells. Implications for the role of interleukin 2 in human B cell function. J Exp Med (1985) 2.14
Molecular dating and biogeography of the early placental mammal radiation. J Hered (2001) 2.13
T-cell growth factor and the culture of cloned functional T cells. Adv Immunol (1981) 2.09
Canine and feline parvoviruses can use human or feline transferrin receptors to bind, enter, and infect cells. J Virol (2001) 2.08
Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest (1998) 2.06
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res (1993) 2.01
Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping. J Virol (1989) 2.00
Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection. J Exp Med (1987) 1.95
Natural antibodies to the human T cell lymphoma virus in patients with cutaneous T cell lymphomas. J Exp Med (1981) 1.84
Polo-like kinase is a cell cycle-regulated kinase activated during mitosis. J Biol Chem (1995) 1.80
Identification of distinct predominant epitopes recognized by myoglobin-specific T cells under the control of different Ir genes and characterization of representative T cell clones. J Immunol (1984) 1.75
The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene (2009) 1.75
Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci U S A (1999) 1.72
Outbreak of Infectious Hepatitis, Apparently Milk-borne. Am J Public Health Nations Health (1946) 1.72
Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood (2001) 1.71
Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol (1998) 1.70
Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J Leukoc Biol (1996) 1.70
Peripheral clonal elimination of functional T cells. Science (1990) 1.69
p53 mutation is associated with progression in follicular lymphomas. Blood (1993) 1.69
Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase. Cell Growth Differ (1994) 1.68
Functional and molecular characteristics of T-cell growth factor. Mol Immunol (1980) 1.66
Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high-dose cyclophosphamide therapy. Blood (1992) 1.66
Murine syngeneic mixed lymphocyte response. I. Target antigens are self Ia molecules. J Exp Med (1981) 1.65
Clonal analysis of the major histocompatibility complex restriction and the fine specificity of antigen recognition in the T cell proliferative response to cytochrome C. J Immunol (1983) 1.63
The relationship between immune interferon production and proliferation in antigen-specific, MHC-restricted T cell lines and clones. J Immunol (1983) 1.61
Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta. J Immunol (1999) 1.61
Identification of human neutrophil-derived cathepsin G and azurocidin/CAP37 as chemoattractants for mononuclear cells and neutrophils. J Exp Med (1997) 1.60
Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. J Immunol (2001) 1.59
Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer (1997) 1.58
Isolation of HTLV-transformed B-lymphocyte clone from a patient with HTLV-associated adult T-cell leukaemia. Nature (1984) 1.58
The control of chemotherapy-induced emesis. Ann Intern Med (1981) 1.55
Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol (1986) 1.55
Immortalized hemopoietic cells with stem cell properties. Immunity (1994) 1.55
Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J Natl Cancer Inst (1993) 1.54
Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol (1991) 1.53
Second-generation integrated genetic linkage/radiation hybrid maps of the domestic cat (Felis catus). J Hered (2003) 1.53
T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J Clin Invest (1996) 1.53
Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility. Oncogene (2006) 1.53
Kappa B site-dependent activation of the interleukin-2 receptor alpha-chain gene promoter by human c-Rel. Mol Cell Biol (1992) 1.52
Small noncleaved cell lymphoma associated with florid epithelioid granulomatous response. A clinicopathologic study of seven patients. Am J Surg Pathol (1993) 1.51
Chemokines regulate T cell adherence to recombinant adhesion molecules and extracellular matrix proteins. J Immunol (1996) 1.51
Transforming growth factor beta is a potent inhibitor of interleukin 1 (IL-1) receptor expression: proposed mechanism of inhibition of IL-1 action. J Exp Med (1990) 1.51
Gene complementation. Neither Ir-GLphi gene need be present in the proliferative T cell to generate an immune response to Poly(Glu55Lys36Phe9)n. J Exp Med (1980) 1.49
Growth hormone as an immunomodulating therapeutic agent. Immunol Today (2000) 1.48
Infection with human immunodeficiency virus type 1 upregulates DNA methyltransferase, resulting in de novo methylation of the gamma interferon (IFN-gamma) promoter and subsequent downregulation of IFN-gamma production. Mol Cell Biol (1998) 1.48
Opiates transdeactivate chemokine receptors: delta and mu opiate receptor-mediated heterologous desensitization. J Exp Med (1998) 1.48
Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli. J Natl Cancer Inst (1995) 1.47
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2. J Clin Oncol (1993) 1.46
Hodgkin's disease following non-Hodgkin's lymphoma. A clinicopathologic and immunophenotypic study of nine cases. Am J Surg Pathol (1993) 1.45